GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (FRA:EZB) » Definitions » Cash-to-Debt

Enzo Biochem (FRA:EZB) Cash-to-Debt : 8.39 (As of Jan. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Enzo Biochem's cash to debt ratio for the quarter that ended in Jan. 2024 was 8.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Enzo Biochem could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Enzo Biochem's Cash-to-Debt or its related term are showing as below:

FRA:EZB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12   Med: 4.87   Max: No Debt
Current: 8.39

During the past 13 years, Enzo Biochem's highest Cash to Debt Ratio was No Debt. The lowest was 0.12. And the median was 4.87.

FRA:EZB's Cash-to-Debt is ranked better than
76.21% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.27 vs FRA:EZB: 8.39

Enzo Biochem Cash-to-Debt Historical Data

The historical data trend for Enzo Biochem's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Enzo Biochem Cash-to-Debt Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.16 1.46 1.92 2.33 11.77

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.12 11.77 9.85 8.39

Competitive Comparison of Enzo Biochem's Cash-to-Debt

For the Diagnostics & Research subindustry, Enzo Biochem's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Cash-to-Debt falls into.



Enzo Biochem Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Enzo Biochem's Cash to Debt Ratio for the fiscal year that ended in Jul. 2023 is calculated as:

Enzo Biochem's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzo Biochem  (FRA:EZB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Enzo Biochem Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (FRA:EZB) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Enzo Biochem (FRA:EZB) Headlines

No Headlines